Payment overview · 2025
General Payments
$996.35
75 reported records · 18 companies
Healthcare provider profile · identity verified
Timothy R Oneill, DO
Allopathic & Osteopathic Physicians|Family Medicine · CLARKSTON, MI · NPI 1033117890
Verified facts
What the public records show
CMS Open Payments records show Timothy R Oneill, DO received $996.35 in general payments during 2025 across 75 reported records.
ABBVIE INC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $214.07 | 21.5% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.26 | 19.4% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.82 | 17.6% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.72 | 6.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.59 | 6.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.11 | 5.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.80 | 3.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.68 | 3.2% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $20.14 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.61 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.76 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.95 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.91 | 1.6% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $15.49 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.00 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.00 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.98 | 1.5% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.46 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $996.35 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $202.80 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.05 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.38 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $110.78 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.86 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.72 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.72 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.59 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.44 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.44 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.44 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.68 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| ACCLARENT AERA Normalized: acclarent aera |
Device | Integra LifeSciences Corporation | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRA AIR Normalized: inspira air |
Device | Integra LifeSciences Corporation | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| RELIEVA SPINPLUS NAV Normalized: relieva spinplus nav |
Device | Integra LifeSciences Corporation | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| TruDi Probe Normalized: trudi probe |
Device | Integra LifeSciences Corporation | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.49 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $9.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 107 |
| Losartan Potassium | Losartan Potassium | 381 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 101 |
| Lisinopril | Lisinopril | 280 | 73 |
| Omeprazole | Omeprazole | 254 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 71 |
| Gabapentin | Gabapentin | 189 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 49 |
| Alprazolam | Alprazolam | 171 | 43 |
| Furosemide | Furosemide | 161 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 46 |
| Potassium Chloride | Potassium Chloride | 158 | 46 |
| Metformin Hcl Er | Metformin Hcl | 144 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 30 |
| Prednisone | Prednisone | 126 | 67 |
| Allopurinol | Allopurinol | 120 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 40 |
| Ezetimibe | Ezetimibe | 116 | 35 |
| Mounjaro | Tirzepatide | 115 | 17 |
| Metformin Hcl | Metformin Hcl | 114 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 24 |
| Famotidine | Famotidine | 103 | 28 |
| Clonazepam | Clonazepam | 102 | 20 |
| Simvastatin | Simvastatin | 96 | 26 |
| Trazodone Hcl | Trazodone Hcl | 96 | 22 |
| Meloxicam | Meloxicam | 95 | 20 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Eliquis | Apixaban | 92 | 26 |
| Lorazepam | Lorazepam | 91 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 24 |
| Glimepiride | Glimepiride | 89 | 26 |
| Finasteride | Finasteride | 87 | 25 |
| Donepezil Hcl | Donepezil Hcl | 86 | 17 |
| Lovastatin | Lovastatin | 83 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 21 |
| Bupropion Xl | Bupropion Hcl | 77 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 13 |
| Sertraline Hcl | Sertraline Hcl | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 48 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 18 |
| Mirtazapine | Mirtazapine | 68 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 12 |
| Azithromycin | Azithromycin | 62 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 21 |
| Januvia | Sitagliptin Phosphate | 60 | 12 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 18 |
| Tramadol Hcl | Tramadol Hcl | 54 | 11 |
| Ondansetron Odt | Ondansetron | 51 | 24 |
| Valsartan | Valsartan | 51 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 16 |
| Atenolol | Atenolol | 48 | 15 |
| Celecoxib | Celecoxib | 48 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 13 |
| Carvedilol | Carvedilol | 43 | 16 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | 12 |
| Nystatin | Nystatin | 42 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 28 |
| Diazepam | Diazepam | 36 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 28 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 17 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 11 |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 19 |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Metaxalone | Metaxalone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Clonidine | Clonidine | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $996.35 · 75 records | ABBVIE INC. | ABRYSVO, ACCLARENT AERA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, EVENITY, GARDASIL 9, Grastek, INSPIRA AIR, JARDIANCE, Kerendia, NEFFY, NURTEC ODT, OTEZLA, Odactra, Ozempic, PREVNAR 20, QULIPTA, RELIEVA SPINPLUS NAV, REPATHA, ROTATEQ, Ragwitek, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TRUMENBA, TZIELD, TruDi Probe, UBRELVY, VAXNEUVANCE, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error